Loading…
Based on limited metadata, the FDA issued a warning letter to Lotus Herbal Supplements on July 6, 2020, regarding products classified as drugs. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The letter falls under FDA's drug regulatory authority, though the specific issuing office is not identified in this metadata. To understand the particular compliance issues cited, the complete warning letter would need to be reviewed.